Lineage Cell Therapeutics Inc. — Director's Dealing 2016

Feb 17, 2016

SEC Form 5 — Annual Statement of Changes in Beneficial Ownership

Issuer: BIOTIME INC (BTX)
CIK: 0000876343
Period of Report: 2015-12-31

Reporting Person: KINGSLEY ALFRED D (Director, See Remarks, 10% Owner)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Shares, no par value	5869755	Direct
Common Shares, no par value	1506905	Indirect
Common Shares, no par value	375351	Indirect

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Option to Purchase Common Shares	$5.13	2016-06-30	Common Shares (50000)	50000	Direct
Option to Purchase Common Shares	$4.60	2017-06-30	Common Shares (50000)	50000	Direct
Option to Purchase Common Shares	$4.13	2018-06-30	Common Shares (50000)	50000	Direct
Option to Purchase Common Shares	$3.11	2019-06-30	Common Shares (50000)	50000	Direct
Option to Purchase Common Shares	$3.57	2020-06-30	Common Shares (50000)	50000	Direct

Footnotes

F1: During 2015, Mr. Kingsley gifted a total of 68,300 common shares.

F2: Does not include shares that Mr. Kingsley may acquire through the exercise of certain options.

F3: 12,500 options became exercisable on September 30, 2011; December 31, 2011; March 31, 2012; and June 30, 2012.

F4: 12,500 options became exercisable on September 30, 2012; December 31, 2012; March 31, 2013; and June 30, 2013.

F5: 12,500 options became exercisable on September 30, 2013; December 31, 2013; March 31, 2014; and June 30, 2014.

F6: 12,500 options became exercisable on September 30, 2014; December 31, 2014; March 31, 2015, and June 30, 2015.

F7: 12,500 options became exercisable on September 30, 2015 and December 31, 2015, and the remaining 25,000 options will become exercisable in 2 equal quarterly installments based upon continued service on the board of directors.